• Users Online: 484
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
MEDICINE AND SOCIETY
Year : 2017  |  Volume : 30  |  Issue : 6  |  Page : 345-347

Intraocular use of bevacizumab in India: An issue resolved?


Dr R.P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India

Correspondence Address:
Rohan Chawla
Dr R.P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-258X.239079

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF), which has been approved for intravenous use in certain cancers. There is evidence of its efficacy and safety as an intravitreal drug compared with ranibizumab and aflibercept. We have, in our practice, found it to be a cost-effective treatment option for ocular diseases, which could save a large amount of public money used in various national health insurance systems. An alert issued by the Drug Controller General of India led to a virtual ban on its intraocular use in India. However, pro-active advocacy and leadership by national ophthalmological societies helped to resolve the issue quickly.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2473    
    Printed29    
    Emailed0    
    PDF Downloaded231    
    Comments [Add]    
    Cited by others 1    

Recommend this journal